Cinemo Expands Best-in-Class Infotainment Portfolio to New Markets at Mobile World Congress 2023
Cinemo, a global leader in high performance and automotive-grade multimedia playback, streaming, media management, connectivity, and cloud middleware, will be showcasing brand new infotainment technology use cases – set to transform how manufacturers deliver screen experiences to their customers – at Mobile World Congress 2023.
With technology trusted by a range of businesses – from the largest high-tech and consumer electronics companies to leading content providers, system integrators, industry associations – and a strong network of partners, Cinemo continues to develop its unique portfolio, for any digital screen.
Cinemo’s established and ongoing success in enabling unparalleled digital media experiences in the complex and competitive automotive market ensures the company is best placed to deliver bespoke use cases in other industries where consumers are engaging with screens on the move.
To provide inspiration for OEMs who want to create their own innovative screen products, the company will be showcasing example use cases to demonstrate how its technology is being used in in-vehicle aftermarket infotainment, connected health and fitness devices, and digital signage, at Booth CS104, Congress Square.
You will be able to experience a variety of real-world scenarios for these markets including:
- BYOD / screen mirroring, which allows content sharing from a personal mobile device to any screen
- Streaming of the world’s leading video-on-demand and music services, delivering optimal consumer choice
- Enabling a multi-seat experience for joint video viewing and gaming
- Synchronized media playback for the most efficient content distribution for use with any screen size and resolution
Whether embedded or delivered through the cloud, Cinemo offers solutions for every implementation requirement. This is achieved by combining high-performance, high-quality, low-footprint, and cutting-edge technologies in a truly system-agnostic design.
“Our experience in automotive has highlighted the increased need for OEMs to be able to deliver fluid, seamless multimedia experiences to enhance the consumer experience, whatever their device category. At MWC we will demonstrate how our technology helps manufacturers in other industries to truly and efficiently differentiate their offerings,” says Tristan Kleiner, Director of Business Development at Cinemo. “We make every screen an opportunity. Whether you’re looking to create an immersive retail experience or provide gym equipment that gives your customers seamless access to the latest streaming services or content from their own device on your device screen – we can help you deliver it.”
To schedule your individual demo meeting with Cinemo at MWC 2023, visit www.cinemo.com/mwc2023
ENDS
About Cinemo
Cinemo is a global leader in high performance and automotive-grade multimedia playback, streaming, media management, connectivity and cloud-access middleware. CPU and operating system agnostic as well as highly optimized for low power and low footprint devices, Cinemo's unified middleware solutions decode, play, render, stream, manage and index virtually any file, disc, connected device, streaming format and cloud content. Designed and optimized for the high-quality requirements of the automotive industry, Cinemo's solutions can be seamlessly integrated into entry, mid and high automotive / in-vehicle infotainment system head and rear-seat units, as well as automotive apps enabling powerful new use cases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005570/en/
Contact information
Martina Oerther
moerther@cinemo.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom